drug safety

FDA
Favicon Fierce Pharma

FDA investigates 2 deaths after Sarepta Duchenne gene therapy

The agency is investigating two Duchenne muscular dystrophy patient deaths following treatment with Sarepta Therapeutics’ Elevidys.
Angus Liu Jun 25, 2025 10:26am
Redbrick building with Sarepta name and logo
Favicon Fierce Pharma

2nd patient dies after Sarepta's DMD gene therapy Elevidys

Jun 16, 2025 10:58am
Magnifying glass with pills on blue

FDA's CMO steps down

Apr 2, 2025 10:02am
cancelled flights

Pliant terminates lung disease trial due to adverse events

Mar 3, 2025 11:30am
Gene editing CRISPR gene therapy

Neurogene acts as gene therapy puts person in critical condition

Nov 18, 2024 8:33am
Caution sign on wet floor

Syndax stock slips after AML drug hits midstage trial goal

Nov 12, 2024 2:00pm